Inventor · disambiguated record
Ralph Markus Wirtz
Also filed as: WIRTZ RALPH · WIRTZ RALPH M · WIRTZ RALPH MARKUS
7 granted patents·30 pending applications·40 citations·filing 2001–2023
76Inventor score
Files withINTELLEXON GMBH7SIEMENS HEALTHCARE DIAGNOSTICS6WIRTZ RALPH MARKUS6WIRTZ RALPH5BIONTECH DIAGNOSTICS GMBH3
Top patents by PatentIndex Score
37 records- 0184US7452727B2Method for increasing clinical specificity when detecting tumors and their precursor stages by simultaneously measuring at least two different molecular markersSIEMENS HEALTHCARE DIAGNOSTICS·Filed 2001·Granted Nov 18, 2008·39 cites·8 claims
- 0272US9683229B2Matrix and method for purifying and/or isolating nucleic acidsWIRTZ RALPH MARKUS·Filed 2014·Granted Jun 20, 2017·1 cites·16 claims
- 0370US2023374609A1Hla-j and medical/diagnostic uses thereofINTELLEXON GMBH·Filed 2023·Application pending·0 cites
- 0466US2010099108A1Method for Detecting, Isolating, and Characterizing Cells from Body Samples by Transfection with Nucleic Acid ConstructsSIEMENS HEALTHCARE DIAGNOSTICS·Filed 2009·Application pending·0 cites
- 0561US9932639B2Method for predicting therapy responsiveness in basal like tumorsWIRTZ RALPH MARKUS·Filed 2008·Granted Apr 3, 2018·0 cites·4 claims
- 0661US2025179579A1Method of detecting urothelial or bladder cancer in a liquid sampleQIAGEN GMBH·Filed 2022·Application pending·0 cites
- 0752US2018251854A1Method For Predicting Therapy Responsiveness In Basal Like TumorsWIRTZ RALPH MARKUS·Filed 2018·Application pending·0 cites
- 0852US2021238690A1Hla-j and medical/diagnostic uses thereofINTELLEXON GMBH·Filed 2018·Application pending·0 cites
- 0950US10808283B2Methods and kits for the molecular subtyping of tumorsBIONTECH DIAGNOSTICS GMBH·Filed 2014·Granted Oct 20, 2020·0 cites·18 claims
- 1050US2020340065A1Methods and kits for the molecular subtyping of tumorsBIONTECH AG·Filed 2020·Application pending·0 cites
- 1148US9376720B2Method to assess prognosis and to predict therapeutic success in cancer by determining hormone receptor expression levelsWIRTZ RALPH·Filed 2011·Granted Jun 28, 2016·0 cites·17 claims
- 1248US8519116B2Method for predicting a clinical response of a patient suffering from or at risk of developing cancer towards a given mode of treatmentWIRTZ RALPH MARKUS·Filed 2009·Granted Aug 27, 2013·0 cites·1 claims
- 1348US2012015827A1Method for therapy prediction in tumors having irregularities in the expression of at least one vegf ligand and/or at least one erbb-receptorWIRTZ RALPH·Filed 2008·Application pending·0 cites
- 1447US2022316014A1Methods for diagnosing the effectiveness of anti-tumor treatmentINTELLEXON GMBH·Filed 2020·Application pending·0 cites
- 1546US8747839B2Tracking of bone marrow cells for metastasis screeningGEPPERT CHRISTIAN·Filed 2010·Granted Jun 10, 2014·0 cites·22 claims
- 1646US2022333193A1Determining individual hla patterns, use as prognosticators, target genes and therapeutic agentsINTELLEXON GMBH·Filed 2020·Application pending·0 cites
- 1746US2008261227A1Kinetic Pcr Assay for Quantification of Gene Amplification on Chromosome 17SIEMENS HEALTHCARE DIAGNOSTICS·Filed 2006·Application pending·0 cites
- 1846US2009215036A1Genetic Alterations Useful For The Response Prediction of Malignant Neoplasia to Taxane-Based Medical TreatmentsBAYER HEALTHCARE AG·Filed 2005·Application pending·0 cites
- 1946US2004219543A1Method for specifically detecting, isolating and characterizing cells from body samples by transfecting nucleic acid constructsWIRTZ RALPH·Filed 2002·Application pending·0 cites
- 2045US2008113344A1Methods and Compositions for the Response Prediction of Malignant Neoplasia to TreatmentWIRTZ RALPH·Filed 2004·Application pending·0 cites
- 2145US2008305962A1Methods and Kits for the Prediction of Therapeutic Success, Recurrence Free and Overall Survival in Cancer TherapiesWIRTZ RALPH MARKUS·Filed 2006·Application pending·0 cites
- 2245US2022145403A1Method of classifying a sample based on determination of fgfrSTRATIFYER MOLECULAR PATHOLOGY GMBH·Filed 2020·Application pending·0 cites
- 2344US2022363767A1Hla-h, hla-j, hla-l, hla-v and hla-y as therapeutic and diagnostic targetsINTELLEXON GMBH·Filed 2020·Application pending·0 cites
- 2444US2022282330A1Hla-h in medicine and diagnosticsINTELLEXON GMBH·Filed 2020·Application pending·0 cites
- 2544US2016355889A1Method to assess prognosis and to predict therapeutic success in cancer by determining hormone receptor expression levelsWIRTZ RALPH·Filed 2016·Application pending·0 cites
- 2643US2022380848A1Hla class i molecules in in vitro fertilization and further medical implicationsINTELLEXON GMBH·Filed 2020·Application pending·0 cites
- 2742US2011033852A1Present invention relates to methods for prediction of the therapeutic success of breast cancer therapyWIRTZ RALPH MARKUS·Filed 2008·Application pending·0 cites
- 2842US2009298061A1Diagnostic Methods for the Prediction of Therapeutic Success, Recurrence Free and Overall Survival in Cancer TherapySIEMENS HEALTHCARE DIAGNOSTICS·Filed 2006·Application pending·0 cites
- 2942US2009280493A1Methods and Compositions for the Prediction of Response to Trastuzumab Containing Chemotherapy Regimen in Malignant NeoplasiaSIEMENS HEALTHCARE DIAGNOSTICS·Filed 2007·Application pending·0 cites
- 3041US2021363594A1Predictive and Prognostic Methods in Breast CancerBIONTECH DIAGNOSTICS GMBH·Filed 2019·Application pending·0 cites
- 3141US2021371936A1Predictive methods in breast cancerBIONTECH DIAGNOSTICS GMBH·Filed 2019·Application pending·0 cites
- 3240US2011229414A1Contrast Agents For Detecting Protease Activity By Means Of Hyperpolarization And For Stratifying PatientsSIEMENS AG·Filed 2011·Application pending·0 cites
- 3338US2012149027A1Method for Determining the Risk of Metastasis as an Indicator for Diagnostic ImagingUNTCH MICHAEL·Filed 2010·Application pending·0 cites
- 3438US2008311567A1Tumor Markers for Use in the Diagnosis of Colorectal Carcinomas and/or Metastases Originating TherefromUNIV FRIEDRICH ALEXANDER ER·Filed 2005·Application pending·0 cites
- 3537US2009150315A1Neoplastic Disease-Related Methods, Kits, Systems and DatabasesSIEMENS HEALTHCARE DIAGNOSTICS·Filed 2006·Application pending·0 cites
- 3636US2002106685A1Method for specifically detecting tumor cells and their precursors in uterine cervical smears by simultaneously measuring at least 2 different molecular markersFiled 2001·Application pending·0 cites
- 3733US2004018525A1Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasmaBAYER AG·Filed 2003·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Ralph Markus Wirtz files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →